v3.26.3
Nature of Business and Basis of Presentation (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue $ 0.5 $ 41.9 $ 265.8 $ 253.1
Cash, cash equivalents, restricted cash and marketable securities 558.9   558.9  
Rigel Pharmaceuticals, Inc. | License revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue $ 0.5 $ 0.0 $ 63.0 $ 0.0